Alcon launched the new monthly multifocal toric contact lens, TOTAL30, the company’s first water‑gradient multifocal toric lens, designed for presbyopic patients with astigmatism. The lens offers a 30‑day replacement schedule and a water‑gradient material that delivers up to 16 hours of comfort on day 30, with a 97% first‑lens fit success rate in clinical studies.
The lens covers a full power range from +6.00 D to –10.00 D, includes three add powers and multiple cylinder options, and targets the 7% of astigmatic presbyopes who currently wear contact lenses. By filling this underserved niche, Alcon aims to capture a growing segment of the U.S. contact‑lens market as the population ages.
The launch aligns with Alcon’s strategy to drive higher‑margin innovation in its vision‑care segment while complementing its surgical business. The new product is expected to generate incremental revenue and support the company’s broader goal of sustaining growth amid a soft U.S. surgical market. Alcon’s vision‑care portfolio already includes other water‑gradient lenses such as PRECISION1 and DAILIES TOTAL1, which have shown double‑digit growth.
Alcon plans to introduce TOTAL30 in select international markets later in 2026, expanding the lens’s reach beyond the United States. The company’s distribution network will make the lens available nationwide to eye‑care professionals, positioning Alcon to strengthen its competitive moat in a market where new entrants are expanding the range of multifocal options.
The introduction of the world’s only water‑gradient multifocal toric lens underscores Alcon’s commitment to solving complex vision challenges and delivering premium contact‑lens solutions to eye‑care professionals and patients.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.